Literature DB >> 34724798

End-of-Life Care for Older Adults with Aggressive Non-Hodgkin Lymphoma.

P Connor Johnson1,2, Netana H Markovitz1, Alisha Yi1,2, Richard A Newcomb1,2, Hermioni L Amonoo2,3, Ashley M Nelson2,4, Matthew J Reynolds4, Julia Rice4, Mitchell W Lavoie4, Oreofe O Odejide2,5, Ryan D Nipp1,2, Areej El-Jawahri1,2.   

Abstract

Background: Aggressive non-Hodgkin lymphoma (NHL) commonly affects older adults and is often treated with intensive therapies. Receipt of intensive therapies and absence of a clear transition between the curative and palliative phases of treatment yield prognostic uncertainty and risk for poor end-of-life (EOL) outcomes. However, data regarding the EOL outcomes of this population are lacking.
Methods: We conducted a retrospective analysis of adults ≥65 years with aggressive NHL treated with systemic therapy at Massachusetts General Hospital from April 2000 to July 2020 who subsequently died. We abstracted patient and clinical characteristics and EOL outcomes from the medical record. Using multivariable logistic regression, we examined factors associated with hospitalization within 30 days of death and hospice utilization.
Results: Among 91 patients (median age = 75 years; 37.4% female), 70.3% (64/91) were hospitalized, 34.1% (31/91) received systemic therapy, and 23.3% (21/90) had an intensive care unit admission within 30 days of death. The rates of palliative care consultation and hospice utilization were 47.7% (42/88) and 39.8% (35/88), respectively. More than half of patients (51.6%, 47/91) died in a hospital or health care facility. In multivariable analysis, elevated lactic acid dehydrogenase was associated with risk of hospitalization within 30 days of death (odds ratio [OR] 3.61, p = 0.014). Palliative care consultation (OR 4.45, p = 0.005) was associated with a greater likelihood of hospice utilization, whereas hypoalbuminemia (OR 0.29, p = 0.026) was associated with a lower likelihood of hospice utilization. Conclusions: Older adults with aggressive NHL often experience high health care utilization and infrequently utilize hospice care at the EOL. Our findings underscore the need for interventions to optimize the quality of EOL care for this population.

Entities:  

Keywords:  elderly; end-of-life outcomes; non-Hodgkin lymphoma

Mesh:

Year:  2021        PMID: 34724798      PMCID: PMC9360173          DOI: 10.1089/jpm.2021.0228

Source DB:  PubMed          Journal:  J Palliat Med        ISSN: 1557-7740            Impact factor:   2.947


  39 in total

1.  Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study.

Authors:  Michael Crump; Sattva S Neelapu; Umar Farooq; Eric Van Den Neste; John Kuruvilla; Jason Westin; Brian K Link; Annette Hay; James R Cerhan; Liting Zhu; Sami Boussetta; Lei Feng; Matthew J Maurer; Lynn Navale; Jeff Wiezorek; William Y Go; Christian Gisselbrecht
Journal:  Blood       Date:  2017-08-03       Impact factor: 22.113

Review 2.  Considerations for the Treatment of Diffuse Large B Cell Lymphoma in the Elderly.

Authors:  Yasir Khan; Elizabeth A Brem
Journal:  Curr Hematol Malig Rep       Date:  2019-08       Impact factor: 3.952

3.  Patterns of hospice use in patients dying from hematologic malignancies.

Authors:  Amy Sexauer; M Jennifer Cheng; Louise Knight; Anthony W Riley; Lauren King; Thomas J Smith
Journal:  J Palliat Med       Date:  2014-01-02       Impact factor: 2.947

4.  Cancer statistics, 2019.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2019-01-08       Impact factor: 508.702

5.  Barriers to Quality End-of-Life Care for Patients With Blood Cancers.

Authors:  Oreofe O Odejide; Angel M Cronin; Nolan B Condron; Sean A Fletcher; Craig C Earle; James A Tulsky; Gregory A Abel
Journal:  J Clin Oncol       Date:  2016-07-11       Impact factor: 44.544

6.  Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial.

Authors:  Frédéric Peyrade; Fabrice Jardin; Catherine Thieblemont; Antoine Thyss; Jean-François Emile; Sylvie Castaigne; Bertrand Coiffier; Corinne Haioun; Serge Bologna; Olivier Fitoussi; Gérard Lepeu; Christophe Fruchart; Dominique Bordessoule; Michel Blanc; Richard Delarue; Maud Janvier; Bruno Salles; Marc André; Marion Fournier; Philippe Gaulard; Hervé Tilly
Journal:  Lancet Oncol       Date:  2011-04-07       Impact factor: 41.316

7.  Place of death: correlations with quality of life of patients with cancer and predictors of bereaved caregivers' mental health.

Authors:  Alexi A Wright; Nancy L Keating; Tracy A Balboni; Ursula A Matulonis; Susan D Block; Holly G Prigerson
Journal:  J Clin Oncol       Date:  2010-09-13       Impact factor: 44.544

8.  Early Versus Delayed Initiation of Concurrent Palliative Oncology Care: Patient Outcomes in the ENABLE III Randomized Controlled Trial.

Authors:  Marie A Bakitas; Tor D Tosteson; Zhigang Li; Kathleen D Lyons; Jay G Hull; Zhongze Li; J Nicholas Dionne-Odom; Jennifer Frost; Konstantin H Dragnev; Mark T Hegel; Andres Azuero; Tim A Ahles
Journal:  J Clin Oncol       Date:  2015-03-23       Impact factor: 44.544

9.  Place of care in advanced cancer: a qualitative systematic literature review of patient preferences.

Authors:  I J Higginson; G J Sen-Gupta
Journal:  J Palliat Med       Date:  2000       Impact factor: 2.947

Review 10.  Strategies for introducing palliative care in the management of relapsed or refractory aggressive lymphomas.

Authors:  Oreofe O Odejide
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2020-12-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.